With Key FDA Recognition and 70% Trial Recruitment, Dimerix (ASX:DXB) Targets Global Growth in FY25

Highlights

• DXB’s 1HFY25 revenue surged 113% YoY to AUD 0.48 million supported by licensing deals.
• Dimerix completed 70% recruitment in its Phase 3 FSGS trial, aiming for 2025 regulatory submissions.
• The company is opening new clinical trial sites in Japan and pursuing additional licensing opportunities.

Dimerix Limited (ASX: DXB) is a clinical-stage biopharma company developing kidney and respiratory disease treatments, with lead candidates DMX-200 in Phase 3 for FSGS and DMX-700 for respiratory conditions, both discovered via its proprietary Receptor-HIT platform.

In the first half of the financial year 2025 (1HFY25), the company’s revenue increased by 113% YoY to AUD 0.48 million, supported by licensing deals such as the one with Fuso Pharmaceutical and progress in clinical trials. Cash and cash equivalents surged by 43% YoY to AUD 21.11 million in 1HFY25, up from AUD 14.81 million in 1HFY24.

However, the company reported a loss of AUD 12.91 million during the reported period, up from AUD 6.67 million in 1HFY24. The widening loss was mainly attributed to elevated R&D expenditures, corporate expenses, and limited licensing revenue.

Business Update

During the quarter ended 31 March 2025, Dimerix secured FDA recognition of proteinuria as a key endpoint for DMX-200 and signed a licensing deal with Fuso Pharmaceutical in Japan worth up to AUD 107 million.

On 13 June 2025, Dimerix reported dosing 70% of patients in its Phase 3 ACTION3 FSGS trial, with 43 completing treatment and joining an extension, while also pursuing global licensing opportunities. The recruitment is expected to be completed in 2025.

Company Outlook

The company is expanding its global footprint by opening new clinical trial sites in Japan and actively seeking additional licensing opportunities to support long-term revenue growth. The company prioritizes DMX-200 development for FSGS, aiming to meet urgent unmet needs under Orphan Drug Designation.

Top 10 Shareholders of DXB  

The top 10 shareholders of DXB holds ~23.18% of the total shareholding. Meurs (Peter Fletcher) and Skiptan Pty. Ltd. have highest stakes in the company with ~7.56% and ~7.27% shareholding, respectively.

Share performance of DXB

Dimerix shares closed at AUD 0.500 on 18 June 2025, down 0.99% for the day. The stock has declined 6.54% over the past week and 10.71% over the last month. The stock has gained 2.05% over the past three months and delivered 47.06% return over the last six months. The stock reached a 52-week high of AUD 0.785 on 5 May 2025 and a low of AUD 0.300 on 23 December 2024.

Support and Resistance Summary

Note 1: Past performance is neither an Indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, and currency, is 18 June 2025. The reference data in this report has been partly sourced from REFINITIV.

Technical Indicators Defined:

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.

Disclaimer

This article has been prepared by Kalkine Media, echoed on the website kalkinemedia.com/au and associated pages, based on the information obtained and collated from the subscription reports prepared by Kalkine Pty. Ltd. [ABN 34 154 808 312; AFSL no. 425376] on Kalkine.com.au (and associated pages). The principal purpose of the content is to provide factual information only for educational purposes. None of the content in this article, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video is or is intended to be, advisory in nature. The content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including but not limited to, in respect of any particular security, transaction, or investment strategy, and must not be relied upon by you as such. The content is provided without any express or implied warranties of any kind. Kalkine Media, and its related bodies corporate, agents, and employees (Kalkine Group) cannot and do not warrant the accuracy, completeness, timeliness, merchantability, or fitness for a particular purpose of the content or the website, and to the extent permitted by law, Kalkine Group hereby disclaims any and all such express or implied warranties. Kalkine Group shall NOT be held liable for any investment or trading losses you may incur by using the information shared on our website.